Timothy Lubenow
Interventional Pain Medicine · Chicago, ILNPI 1922024470
Payments from drug & device makers
Across 1,622 payments — averaging $527.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$415K
- Boston Scientific$235K
- Nevro Corp.$75K
- Vertiflex, Inc.$72K
- Biotronik NRO, Inc.$15K
- Painteq LLC$12K
- plus $32K from 26 others
Across 2 payments — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nevro Corp.$1K
What the payments were for
- Consulting fees$108,41919%
- Speaking & faculty fees$338,36161%
- Travel & lodging$47,5319%
- Food & beverage$59,89611%
- Education$1,9460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 967 | $414,744 |
| Boston Scientific | 231 | $235,456 |
| Nevro Corp. | 147 | $74,998 |
| Vertiflex, Inc. | 56 | $71,648 |
| Biotronik NRO, Inc. | 45 | $14,975 |
| Painteq LLC | 15 | $12,214 |
| Medtronic(2 entities) | 26 | $10,909 |
| AbbVie(2 entities) | 48 | $7,848 |
| Flowonix Medical Incorporated | 1 | $5,506 |
| Spinal Simplicity, LLC | 17 | $2,991 |
| SPR Therapeutics, Inc | 9 | $759 |
| Relievant Medsystems, Inc. | 8 | $758 |
| Saluda Medical Americas, Inc. | 3 | $555 |
| MML US, Inc. | 8 | $444 |
| Vertos Medical, Inc. | 3 | $349 |
| Nalu Medical, Inc. | 3 | $254 |
| Curonix LLC | 2 | $220 |
| Tersera Therapeutics LLC | 4 | $201 |
| Globus Medical | 3 | $197 |
| Stimwave Technologies Incorporated | 1 | $117 |
| Collegium Pharmaceutical, Inc. | 7 | $114 |
| Pfizer | 5 | $100 |
| GRT US Holding, Inc. | 1 | $95 |
| Biotronik Inc. | 1 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $70 |
| Si-bone, Inc. | 1 | $36 |
| Pacira Pharmaceuticals Incorporated | 1 | $32 |
| Redhill Biopharma Inc. | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$98,181
- Neuromodulation Dspsbls and Accs$77,337
- Senza Spinal Cord Stimulation System$44,895
- SUPERION$42,929
- Superion Indirect Decompression System$28,767
- Proclaim Family of SCS IPGs$27,067
- Superion ISS$26,003
- Omnia$20,758
- Prospera$14,161
- Axium INS DRG IPG$12,403
- SPECTRA WAVEWRITER$11,544
- GENERAL - THERAPIES$8,833
- PAINTEQ$7,120
- UBRELVY$6,733
- GENERAL PAIN MANAGEMENT$6,650
- Proclaim IPG$5,905
- Prometra II$5,506
- WAVEWRITER ALPHA$5,500
- RESTORE$5,390
- GENERAL VASCULAR ACCESS$4,870
How this compares
$855,757 in reported general payments places this provider in the 95th percentile of 93 interventional pain medicine providers in Illinois.
See all interventional pain medicine providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 681 | $19,890 |
| Ms ContinMorphine Sulfate | 18 | $18,368 |
| MovantikNaloxegol Oxalate | 35 | $14,304 |
| Pregabalin | 383 | $9,372 |
| Oxycodone Hcl | 225 | $6,756 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 150 | $6,101 |
| Fentanyl | 79 | $5,633 |
| Morphine Sulfate ErMorphine Sulfate | 194 | $5,507 |
| OxycontinOxycodone Hcl | 18 | $5,048 |
| Gabapentin | 301 | $4,945 |
| Celecoxib | 105 | $4,764 |
| Buprenorphine | 29 | $4,647 |
| Tizanidine Hcl | 312 | $4,146 |
| Lidocaine | 44 | $3,953 |
| Baclofen | 148 | $3,235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $28 | $14,30435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 93 interventional pain medicine providers in Illinois.
Other interventional pain medicine in Chicago
- Kenneth CandidoChicago$509K
- Sandeep AminChicago$430K
- Asokumar BuvanendranChicago$182K
- Matthew JaycoxChicago$129K
- Hong VoChicago$91K
- Adam YoungChicago$29K
- Salman SagarwalaChicago$26K
- Sameer ShahChicago$10K
- James DiesfeldChicago$10K
- Xiaoyuam XieChicago$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.